ROSE Diagnostics的封面图片
ROSE Diagnostics

ROSE Diagnostics

生物技术研究

Carlsbad，CA 39 位关注者

Revolutionizing Cancer Biopsies with Point-of-Care Testing Solutions.

关注

关于我们

ROSE Diagnostics was created in California in 2023 with a visionary idea at its core - to address an unmet need in healthcare by bridging the gap between pathology labs and cancer biopsy clinics. Recognizing the potential to significantly improve patient outcomes, we conceptualized a unique approach to diagnostic testing. At the heart of our journey is a team of founders who are leaders in the diagnostics industry, boasting a collaborative history marked by many successful product launches. ROSE Diagnostics is comprised of like-minded scientists, product developers, clinical partners, business leaders, and regulatory experts. Our team brings 20+ years of experience and knowledge to the table, embodying a collective expertise geared towards making a meaningful impact on diagnostic practices.

网站
rose-dx.com
所属行业
生物技术研究
规模
2-10 人
总部
Carlsbad，CA
类型
私人持股

地点

ROSE Diagnostics员工

查看全部员工

动态

  • To kick off the new year and share our story with new investors, we're inviting you to join us for a webinar session with our CEO Andrew Morris and CSO Eric Brouwer. On January 30th at 1:00 pm EST / 10:00 am PST there will be a short presentation outlining what we do, who we are, and what we have in store for 2025, followed by a Q&A Session. If you are interested in learning more about us, please click the link below to sign up for this webinar session: https://lnkd.in/g5EcYCra

  • ???????? ???????? ?????????????????????? ???? ?????? ?????????????? ???? ?????????????????????????? ???????????? ???????????????? ???????? ??????????-???? ???????? ?????????????? ?????????????????? https://lnkd.in/gbTWYH6Z ?????? ?????????????? During a typical lung cancer biopsy, collected specimens are sent to a pathology lab to verify the correct tissue was collected for an analysis and diagnosis. If that tissue sample is insufficient for analysis, the patient must undergo another bronchoscopy biopsy, repeating the process. This costs the patient unnecessary stress, medical fees, and time until treatment. ?????? ???????????????? We’ve created a 5-minute test using a panel of known lymph node biomarkers in a rapid point-of-care test format. With our disposable verifi? LUNG Test cartridges and portable reader, clinicians can verify that they collected adequate specimens during the biopsy procedure, right there and then. ?????????? ???? We’ve assembled a world class team of leaders in the diagnostics industry to make our mission happen. With 20+ years of experience in point of care diagnostics, the ROSE Diagnostics team embodies the collective expertise geared to making a meaningful impact on improving cancer diagnostic outcomes. ???????????????? We closed our $1 million seed-funding in June 2024 and are collecting our first clinical study samples this week. We’ve also just launched our crowdfunding campaign on StartEngine, an equity crowdfunding platform that allows startups and small businesses to raise capital by offering shares to the public. This opportunity will allow anyone - not just accredited investors - to play an important role in the future of faster, more accurate cancer testing. We’ll use these funds to complete internal product development and get us to our pivotal study launch in Q1 2025. This will position us to be able to commercialize the verifi LUNG Test system. ???? ???????? ?????? ???????? ?????????? ????, ?????????? ?????? ???????????????? ???????? ???? ?????????????????????? ??????????.

相似主页

查看职位